Inovio Pharmaceuticals Net Income 2006-2021 | INO

Inovio Pharmaceuticals net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Inovio Pharmaceuticals Annual Net Income
(Millions of US $)
2020 $-166
2019 $-119
2018 $-97
2017 $-88
2016 $-74
2015 $-29
2014 $-36
2013 $-66
2012 $-20
2011 $-15
2010 $-18
2009 $-24
2008 $-13
2007 $-11
2006 $-14
2005 $-26
Inovio Pharmaceuticals Quarterly Net Income
(Millions of US $)
2021-06-30 $-82
2021-03-31 $-54
2020-12-31 $-24
2020-09-30 $19
2020-06-30 $-129
2020-03-31 $-33
2019-12-31 $-38
2019-09-30 $-23
2019-06-30 $-29
2019-03-31 $-29
2018-12-31 $-33
2018-09-30 $-25
2018-06-30 $-7
2018-03-31 $-32
2017-12-31 $-22
2017-09-30 $-34
2017-06-30 $-9
2017-03-31 $-23
2016-12-31 $-26
2016-09-30 $-21
2016-06-30 $-19
2016-03-31 $-8
2015-12-31 $-18
2015-09-30 $6
2015-06-30 $-6
2015-03-31 $-11
2014-12-31 $-7
2014-09-30 $-7
2014-06-30 $-11
2014-03-31 $-11
2013-12-31 $-15
2013-09-30 $-31
2013-06-30 $-11
2013-03-31 $-9
2012-12-31 $-1
2012-09-30 $-7
2012-06-30 $-4
2012-03-31 $-8
2011-12-31 $-5
2011-09-30 $-5
2011-06-30 $-3
2011-03-31 $-2
2010-12-31 $-6
2010-09-30 $-1
2010-06-30 $-8
2010-03-31 $-2
2009-12-31 $-7
2009-09-30 $-3
2009-06-30 $-11
2009-03-31 $-3
2008-12-31 $-4
2008-09-30 $-2
2008-06-30 $-4
2008-03-31 $-3
2007-12-31 $-1
2007-09-30 $-3
2007-06-30 $-4
2007-03-31 $-4
2006-12-31 $-8
2006-09-30 $-3
2006-06-30 $-3
2006-03-31
2005-12-31 $-12
2005-09-30 $-3
2005-06-30 $-2
2005-03-31 $-9
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.481B $0.007B
Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48